[6-K] Novo-Nordisk A/S Current Report (Foreign Issuer)
Novo Nordisk (NVO) filed a Form 6-K disclosing insider transactions under EU Market Abuse Reg.
Rhea-AI Filing Summary
Novo Nordisk (NVO) filed a Form 6-K disclosing insider transactions under EU Market Abuse Reg. 19. Executive Vice President Martin Holst Lange sold company B-shares on 7 Aug 2025 in two separate trades:
- 74 shares at DKK 316.75 (total DKK 23,439.50)
- 13,950 shares at DKK 316.48 (total DKK 4,414,898.43)
The combined sale amounts to 14,024 shares valued at DKK 4.44 million (≈ USD 0.65 million). One trade was executed through Citigroup Global Markets Europe AG; the larger block was carried out outside a trading venue. No purchases, option exercises, or other corporate events were reported, and no financial performance data accompanied the filing. The disclosure fulfills statutory reporting obligations but does not indicate any change in strategy, guidance, or fundamentals.
Positive
- None.
Negative
- Executive share sale could be perceived negatively by some investors despite its immaterial size relative to Novo Nordisk’s market capitalisation.
Insights
TL;DR: EVP sold ~14k shares (DKK 4.4 m); immaterial to valuation but may signal modest profit-taking.
The transaction equals roughly 0.0002 % of Novo Nordisk’s ~5.0 bn outstanding shares and less than one day’s average NOK volume, suggesting negligible dilution or liquidity impact. Insider sales can trigger sentiment concerns, yet the small size and absence of multiple executives reduce interpretive weight. No new financials, pipeline updates, or strategic moves were released; therefore, the filing is largely procedural. I view the impact as neutral with a slight negative tilt driven solely by optics.
TL;DR: Routine MAR 19 disclosure; governance practices remain strong.
Novo Nordisk continues timely reporting of PDMR transactions, reinforcing transparency. The power-of-attorney arrangement centralises disclosure and limits compliance risk. Transaction outside a regulated venue is permitted but warrants investor attention to ensure best execution. No pattern of aggressive insider selling is evident. Overall governance posture is unaffected.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What was the total value of the insider sale disclosed by NVO?
Does the Form 6-K include any earnings or guidance updates?
Where were the transactions executed?
Is this insider sale material to Novo Nordisk investors?
AI-generated analysis. How Rhea-AI works. Not financial advice.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
________________
FORM 6-K
________________
REPORT OF FOREIGN PRIVATE ISSUER
Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934
August 7, 2025
________________
NOVO NORDISK A/S
(Exact name of Registrant as specified in its charter)
Novo Allé 1
DK- 2880, Bagsvaerd
Denmark
(Address of principal executive offices)
________________
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F
| Form 20-F ☒ | Form 40-F ☐ |
Trading in Novo Nordisk shares by board members, executives and associated persons
Bagsværd, Denmark, 7 August 2025 — This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company’s board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse.
The company’s board members, executives and their associated persons have reported the transactions to Novo Nordisk and have given Novo Nordisk power of attorney on their behalf to publish trading in Novo Nordisk shares by the company’s board members, executives and their associated persons.
Please find below a statement of such trading in shares issued by Novo Nordisk.
Page 2 of 4
| 1 | Details of the person discharging managerial responsibilities/person closely associated | ||||
| a) | Name of the Board member/Executive/Associated Person | Martin Holst Lange | |||
| 2 | Reason for the notification | ||||
| a) | Position/status | Executive Vice President | |||
| b) | Initial notification/Amendment | Initial notification | |||
| 3 | Details of the issuer | ||||
| a) | Name | Novo Nordisk A/S | |||
| b) | LEI | 549300DAQ1CVT6CXN342 | |||
| 4 | Details of the transaction(s) | ||||
| a) | Description of the financial instrument, type of instrument, |
Shares | |||
| Identification code | Novo Nordisk B DK0062498333 | ||||
| b) | Nature of the transaction | Sale of shares | |||
| c) |
Price(s) and volume(s) |
||||
| Price(s) | Volume(s) | ||||
| DKK 316.75 | 74 | ||||
| d) |
Aggregated information
|
74 shares DKK 23,439.50 |
|||
| e) | Date of the transaction | 2025-08-07 | |||
| f) | Place of the transaction | (CGET) CITIGROUP GLOBAL MARKETS EUROPE AG - EMEA TRADING |
|||
Page 3 of 4
| 1 | Details of the person discharging managerial responsibilities/person closely associated | ||||
| a) | Name of the Board member/Executive/Associated Person | Martin Holst Lange | |||
| 2 | Reason for the notification | ||||
| a) | Position/status | Executive Vice President | |||
| b) | Initial notification/Amendment | Initial notification | |||
| 3 | Details of the issuer | ||||
| a) | Name | Novo Nordisk A/S | |||
| b) | LEI | 549300DAQ1CVT6CXN342 | |||
| 4 | Details of the transaction(s) | ||||
| a) | Description of the financial instrument, type of instrument, |
Shares | |||
| Identification code | Novo Nordisk B DK0062498333 | ||||
| b) | Nature of the transaction | Sale of shares | |||
| c) |
Price(s) and volume(s) |
||||
| Price(s) | Volume(s) | ||||
| DKK 316.48 | 13,950 | ||||
| d) |
Aggregated information
|
13,950 shares DKK 4,414,898.43 |
|||
| e) | Date of the transaction | 2025-08-07 | |||
| f) | Place of the transaction | Outside a trading venue | |||
Novo Nordisk is a leading global healthcare company founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines and working to prevent and ultimately cure disease. Novo Nordisk employs about 78,400 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Instagram, X, LinkedIn and YouTube.
Page 4 of 4
Contacts for further information
| Media: | |
Ambre James-Brown +45 3079 9289 abmo@novonordisk.com |
Liz Skrbkova (US) +1 609 917 0632 lzsk@novonordisk.com |
| Investors: | |
Jacob Martin Wiborg Rode +45 3075 5956 jrde@novonordisk.com |
Sina Meyer +45 3079 6656 azey@novonordisk.com |
|
Max Ung +45 3077 6414 mxun@novonordisk.com |
Christoffer Sho Togo Tullin +45 3079 1471 cftu@novonordisk.com |
|
Alex Bruce +45 3444 2613 axeu@novonordisk.com |
Frederik Taylor Pitter +1 609 613 0568 fptr@novonordisk.com |
Novo Nordisk A/S Investor Relations | Novo Allé 1 2880 Bagsværd Denmark | Telephone: +45 4444 8888 | www.novonordisk.com |
| Company announcement No 21/ 2025 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf of the undersigned, thereunto duly authorized.
| Date: August 7, 2025 |
NOVO NORDISK A/S
Maziar Mike Doustdar Chief Executive Officer |